Philips advances ultrasound portfolio with new robust imaging tools and features for Radiology to increase diagnostic confidence and workflow efficiency
16 Novembre 2021 - 03:00PM
Philips advances ultrasound portfolio with new robust imaging tools
and features for Radiology to increase diagnostic confidence and
workflow efficiency
November 16, 2021
- Advanced diagnostics for the early detection of liver disease
on the company’s ultrasound systems EPIQ Elite and Affiniti receive
FDA 510(k) clearance
- New Philips Liver Fat Quantification allows non-invasive
diagnosis of early-stage fatty liver disease
- Collaboration Live telehealth solution brings remote diagnosis
to mobile platforms including iOS, Android and Chrome
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced it has received 510(k) clearance from the U.S. Food and
Drug Administration (FDA) for its new Liver Fat Quantification
tools as part of the latest release of its ultrasound systems EPIQ
Elite and Affiniti, bringing the cost and accessibility advantages
of sonography to the diagnosis of early-stage liver disease.
Featured at this year’s Radiological Society of North America
(RSNA) annual meeting (November 23 – December 2, Chicago, USA), the
new tools will allow clinicians to track liver health.
Fatty liver disease is the most common and earliest stage of
chronic liver disease. The incidence of non-alcoholic fatty liver
disease (NAFLD) is increased by various risk factors, including
Type 2 diabetes and obesity. It is estimated that NAFLD may be
present in about 25% of the global population [1]. NAFLD includes
milder fatty liver disease, as well as more severe forms that
include inflammation, a condition called Non-Alcoholic
Steatohepatitis (NASH), and fibrosis. Research suggests that early
intervention enables patients to adopt lifestyle changes that can
help to prevent liver disease [1], while early assessment of fatty
liver is key to potentially reversing this progression of liver
disease [2].
"With a quantitative way of measuring liver fat, it is a lot
easier for us to let the referring physician know where the patient
is quantitatively on the NAFLD spectrum,” said Richard G. Barr, MD,
PhD, President, Radiology Consultant, Inc., Youngstown, Ohio,
U.S.A., and Medical Director at Southwoods Imaging. “With
traditional gray scale imaging, we could only tell if the liver had
a high degree of fatty infiltration or if it was normal, but it was
very hard to assess whether fatty liver disease was mild, moderate
or severe. Attenuation imaging now gives us a numerical value that
will enable us to follow the patient over time. With the
combination of quantitative fat assessment and liver stiffness the
probability of NASH can be assessed.”
With the extended remote functionality of Collaboration Live on
both the EPIQ and Affiniti platforms, technicians can also securely
access on-demand, real-time guidance and decision support to
enhance diagnostic confidence and workflow efficiency during
exams.
“Today’s announcement demonstrates the continued advancement of
our ultrasound portfolio to increase diagnostic confidence and
workflow efficiency,” said Jeff Cohen, General Manager of
Ultrasound at Philips. “Accessible ultrasound-based Liver Fat
Quantification is a screening and early diagnostic tool that will
allow many more patients to take their health into their own hands
by making simple lifestyle changes.”
Enhancing the diagnosis and treatment of early-stage and
advanced liver diseasePhilips Ultrasound Systems EPIQ and
Affiniti on Release 9.0 now support radiologists and hepatologists
in the diagnosis and treatment from early-stage to advanced liver
disease, making it easier to perform longitudinal studies to assess
liver disease progression. With this latest release, the company
further strengthens its liver solution and expands its full
availability to the Affiniti 70 and Affiniti 50 – supported by the
innovative PureWave C5-1 Curved transducer, now also available on
Affiniti 50 – to enhance diagnostic confidence in abdominal,
hepatology, and vascular and gynaecological ultrasound exams as
well. The new Liver Fat Quantification tools complement the
company’s existing ultimate solution for liver assessment with
real-time shear wave imaging, contrast enhanced ultrasound (CEUS)
and fusion and navigation. The Liver Fat Quantification tools,
which feature ease of use plus intuitive workflow and reporting, is
available on both the C5-1 and the small footprint mC7-2
MicroConvex transducer, to accommodate different body types, from
smaller patients to high BMI patients [3].
Launch of Philips’ Liver Fat Quantification solution at
RSNA 2021Philips will debut its Liver Fat Quantification
solution at the Radiological Society of North America (RSNA) Annual
Meeting later this month. For more information on Philips Liver Fat
Quantification, including live demos, follow @PhilipsLiveFrom for
updates throughout the RSNA event. For more information on Philips’
portfolio of liver ultrasound solutions, visit the Philips liver
assessment webpage, and join Philips at RSNA 2021 where the company
will spotlight its latest portfolio of radiology workflow solutions
and smart connected imaging systems to increase efficiency and
diagnostic confidence in precision care and treatment.
[1] Asrani et al. Burden of liver disease in the world. J
Hepatology. 2019;1.[2] Younossi ZM. Non-alcoholic fatty liver
disease – A global public health perspective. J Hepatol.
2019;70(3):531-544.[3] Chen J. Realizing dramatic improvements in
the efficiency, sensitivity and bandwidth of ultrasound
transducers. Koninklijke Philips Electronics N.V. 2006.
For further information, please contact:
Kathy O’ReillyPhilips Global Press OfficeTel.: +1
978-221-8919E-mail: kathy.oreilly@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 17.3 billion and
employs approximately 78,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Liver Fat Quantification tool
- EPIC Ultrasound GI Liver image 1
- EPIC Ultrasound GI Liver image 2
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Koninklijke Philips NV (EU:PHIA)
Storico
Da Mar 2023 a Mar 2024